ライフサイエンスコーパス: pneumococcal vaccine

1 is B; and Haemophilus influenzae type b) and pneumococcal vaccine.

2 for liver transplantation routinely receive pneumococcal vaccine.

3 obulin loci, XenoMouse, to PPS antigens in a pneumococcal vaccine.

4 ve poor responses to the currently available pneumococcal vaccine.

5 nd both types are included in the polyvalent pneumococcal vaccine.

6 PspAs for inclusion in a broadly protective pneumococcal vaccine.

7 niae causing bacteremia are contained in the pneumococcal vaccine.

8 89% of PNSP were serotypes in the 23-valent pneumococcal vaccine.

9 12 levels had impaired antibody responses to pneumococcal vaccine.

10 meric subjects generated immune responses to pneumococcal vaccine.

11 frequency has been reduced by the conjugate pneumococcal vaccine.

12 posal of the use of the pilus as a candidate pneumococcal vaccine.

13 complicated the development of an effective pneumococcal vaccine.

14 nt with SLE who had just previously received pneumococcal vaccine.

15 e in the years pre- and post-introduction of pneumococcal vaccine.

16 et initiated vaccination with the conjugated pneumococcal vaccine.

17 care who had been vaccinated with conjugated pneumococcal vaccine.

18 adults, we assessed the effectiveness of the pneumococcal vaccine.

19 nd data from a recent study on influenza and pneumococcal vaccines.

20 HIB-conjugate, tetanus toxoid and 23-valent pneumococcal vaccines.

21 ge is essential for evaluating the impact of pneumococcal vaccines.

22 d adaptive immune responses to influenza and pneumococcal vaccines.

23 lular pertussis, meningococcal conjugate and pneumococcal vaccines.

24 omise for rational design of live-attenuated pneumococcal vaccines.

25 han 90% who strongly recommend influenza and pneumococcal vaccines.

26 nsideration for addition to future conjugate pneumococcal vaccines.

27 city of protein antigens of potential use in pneumococcal vaccines.

28 in the currently available 23- and 7-valent pneumococcal vaccines.

29 owed by one dose of 23-valent polysaccharide pneumococcal vaccine (23-PS).

30 d by serotypes in the seven-valent conjugate pneumococcal vaccine (71.5% from 1989-1993 and 58.3% fro

31 GAVI's Pneumococcal vaccines Accelerated Development and Introd

32 reminders for increasing both influenza and pneumococcal vaccine administration.

33 Based on our results, revaccination with pneumococcal vaccines after transplantation should be co

34 cination for young children, the efficacy of pneumococcal vaccine against invasive disease, and new i

35 between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown.

36 After residents received pneumococcal vaccine and prophylactic antibiotics, there

37 Increased use of pneumococcal vaccine and recognition of antimicrobial re

38 uating risk factors that indicate a need for pneumococcal vaccine and the initiation of annual influe

39 nders have a general inability to respond to pneumococcal vaccine and to determine whether elderly lo

40 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against v

41 Tetanus booster vaccine, pneumococcal vaccine, and intracutaneous skin tests were

42 To address this risk, they receive pneumococcal vaccines, and antibiotic prophylaxis and tr

43 sure of the protective immunity induced with pneumococcal vaccines, and the absence of a partially cr

44 to hepatitis B, tetanus and diphtheria, and pneumococcal vaccines; and autoantibodies to DNA and thy

45 The only pneumococcal vaccine approved to date for children young

46 Since pneumococcal vaccines are designed to elicit antibodies

47 Pneumococcal vaccines are increasingly relevant.

48 core prediction rule in the era of conjugate pneumococcal vaccine as an accurate decision support too

49 nes at 3, 6, 12, and 24 months and 23-valent pneumococcal vaccine at 12 and 24 months.

50 m can identify not only all the serotypes in pneumococcal vaccines but also most (>90%) of clinical i

51 family to bacterial adherence and identify a pneumococcal vaccine candidate.

52 Pneumococcal vaccines contain serotype 6B but not seroty

53 Pneumococcal vaccines containing protein-conjugated olig

54 Pneumococcal vaccine coverage of OPSI patients was low o

55 eactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 microgram each o

56 that integrating evolutionary thinking into pneumococcal vaccine design will lead to the avoidance o

57 x1 PspA is currently under consideration for pneumococcal vaccine development.

58 ponders, revaccination with a double dose of pneumococcal vaccine did not stimulate IgG responses.

59 Studies of pneumococcal vaccine efficacy against colonization have

60 serotyping clinical isolates for evaluating pneumococcal vaccine efficacy.

61 y variable, and this should be considered in pneumococcal vaccine evaluations or when capsular polysa

62 tal C57BL/6 mice immunized with a PC-bearing pneumococcal vaccine expressed increased frequencies of

63 The molecular mechanism of pneumococcal vaccine failure in human immunodeficiency v

64 how promise as components in next-generation pneumococcal vaccine formulations.

65 A whole-cell killed unencapsulated pneumococcal vaccine given by the intranasal route with

66 antly more patients who failed to respond to pneumococcal vaccine had low IgG2 concentrations (p=0.02

67 ized donors, whereas donor immunization with pneumococcal vaccine had no effect on antibody concentra

68 A pneumococcal vaccine has been recommended in the United

69 e introduction of the conjugate seven-valent pneumococcal vaccine has led to the replacement of vacci

70 A new generation of pneumococcal vaccines has been developed, linking the ca

71 The introduction of serotype-specific pneumococcal vaccines has reduced the burden of disease

72 of different pneumococcal serotypes as newer pneumococcal vaccines have been introduced.

73 Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in

74 Currently, published trials of conjugated pneumococcal vaccines have shown the effectiveness and s

75 aureus colonization among children receiving pneumococcal vaccine implicate Streptococcus pneumoniae

76 betic patients who received a single dose of pneumococcal vaccine improved from 24% in 1987 to 1988 t

77 he highly effective introduction of the PCV7 pneumococcal vaccine in 2000 in the United States(2,3) p

78 vered prior to introduction of the conjugate pneumococcal vaccine in 2000; the earliest isolate was r

79 reason for the deficient immune response to pneumococcal vaccine in aged mice is a quantitative defe

80 cine significantly reduces rates of invasive pneumococcal vaccine in healthy and HIV-infected childre

81 es suggest a potential role for the 7-valent pneumococcal vaccine in HIV-infected adults.

82 sis and improve the clinical efficacy of the pneumococcal vaccine in patients with low vitamin B12 le

83 studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malaw

84 Our data support the introduction of pneumococcal vaccine in sub-Saharan Africa.

85 this approach to improve the performance of pneumococcal vaccine in the elderly, we evaluated pneumo

86 fficacy of the currently available 23-valent pneumococcal vaccine in the growing population of adults

87 per dose, purchase and accelerated uptake of pneumococcal vaccine in the world's poorest countries is

88 of controlled clinical evaluations of newer pneumococcal vaccines in all high-risk groups for whom p

89 Many lots of pneumococcal vaccines, including the heptavalent conjuga

90 llows saccharide quantitation in multivalent pneumococcal vaccine intermediates and final drug produc

91 ratory syncytial virus (RSV) seasons, before pneumococcal vaccine introduction.

92 ae and S. aureus disease incidence following pneumococcal vaccine introduction.

93 ecognized in nursing homes, and wider use of pneumococcal vaccine is important to prevent institution

94 Because pneumococcal vaccine is routinely given to HIV-1-infecte

95 The Advanced Market Commitment for pneumococcal vaccines is a so-called pull mechanism that

96 Haemophilus influenzae type b conjugate, and pneumococcal vaccines is included in this first of two a

97 Pneumococcal vaccine may be most protective when it is a

98 he possibilities that whole-cell inactivated pneumococcal vaccines may confer cross-protection to mul

99 tion of this mutant pneumolysin into current pneumococcal vaccines may increase their efficacy.

100 Pneumococcal vaccine-naive mother-child dyads in South A

101 The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was investigated

102 Pneumococcal vaccines need to include more serotypes to

103 nd the impact of vaccination with conjugated pneumococcal vaccine, on the occurrence of serious bacte

104 ough they were found to be associated to the pneumococcal vaccine only in previous analyses.

105 cells from mice vaccinated with a 23-valent pneumococcal vaccine or a PPS 3-bovine serum albumin con

106 vaccine or a control (meningococcal vaccine, pneumococcal vaccine, or placebo).

107 Heptavalent protein-conjugate pneumococcal vaccine (PCPV-7) was then administered, and

108 We studied PPV, protein-conjugate pneumococcal vaccine (PCV), and immunologic "priming" wi

109 ultaneous vaccination with TIV and 13-valent pneumococcal vaccine (PCV13) in children who were 6 to 2

110 rage of serotypes in the 13-valent conjugate pneumococcal vaccine (PCV13) was high, some non-PCV13-em

111 (Hib-TT) vaccine at 2-3-4 months, 13-valent pneumococcal vaccine (PCV13, CRM-conjugated) at 2-4 mont

112 monia following introduction of the 7-valent pneumococcal vaccine (PCV7) are sparse, especially in ad

113 The introduction of the 7-valent conjugate pneumococcal vaccine (PCV7) in children may result in se

114 000, the year of 7-valent protein-conjugated pneumococcal vaccine (PCV7) introduction (139 versus 55

115 ne (TIV; delivered to mothers) plus 7-valent pneumococcal vaccine (PCV7; delivered to infants) was hi

116 even-valent polysaccharide protein conjugate pneumococcal vaccine (PnCRM7) against such disease.

117 to be used in preparation of the polyvalent pneumococcal vaccine PNEUMOVAX 23.

118 ts had vigorous immune responses to selected pneumococcal vaccine polysaccharides, a subset of elderl

119 Influenza and pneumococcal vaccines reduce secondary infections within

120 valuated the effect of age and CMV status on pneumococcal vaccine responses in 348 individuals aged 5

121 not directly responsible for the decline in pneumococcal vaccine responses seen with age but suggest

122 f sera from mice vaccinated with a 23-valent pneumococcal vaccine revealed that they produced serotyp

123 Immediate replacement of pneumococcal vaccine serotypes with non-vaccine serotype

124 Patients with standing orders received a pneumococcal vaccine significantly more often (51%) than

125 Pneumococcal vaccine significantly reduces rates of inva

126 than 5 times as likely to have received the pneumococcal vaccine than the control group (44/221 [19.

127 Development of a pneumococcal vaccine that is immunogenic in young childr

128 or the development of a serotype-independent pneumococcal vaccine that would reduce pneumococcal carr

129 l Microbiology underscore the limitations of pneumococcal vaccines that target the polysaccharide cap

130 ions for the long-term efficacy of conjugate pneumococcal vaccines that will protect against only a l

131 ral recommended guidelines for administering pneumococcal vaccine to HIV-infected persons.

132 hese data support recommendations to provide pneumococcal vaccine to persons in these at-risk groups

133 re obtained from pediatric participants in a pneumococcal vaccine trial.

134 could help us predict the effects of future pneumococcal vaccine use in children on disease rates in

135 athogen as Haemophilus influenzae type b and pneumococcal vaccine use in Mali has diminished invasive

136 ucture of antibodies elicited by a 23-valent pneumococcal vaccine was analyzed.

137 Receipt of the pneumococcal vaccine was associated with a significant r

138 rt of men aged 45 years or older, receipt of pneumococcal vaccine was not associated with subsequent

139 protective antigens were deleted, the killed pneumococcal vaccine was still protective.

140 HIV-infected men immunized with pneumococcal vaccine were classified as high- or low-lev

141 en (KLH) and T cell-independent responses to pneumococcal vaccine were decreased, but many patients w

142 bulin G (IgG) subclass antibody responses to pneumococcal vaccines were determined for human subjects

143 lular and humoral responses to influenza and pneumococcal vaccines were evaluated in 51 chronic phase

144 Currently available pneumococcal vaccines were examined for contamination by

145 iotics, and development and use of effective pneumococcal vaccines will be required to treat and prev

146 re 4 times more likely to have discussed the pneumococcal vaccine with their physicians than patients

147 Pneumococcal vaccines with more robust and sustained imm

148 of these patients had received the 23-valent pneumococcal vaccine within the previous 5 years.